<scp>EGFR</scp> p. <scp>V774M</scp> /p. the <scp>S768I</scp> Compound Mutation in <scp>NSCLC</scp> Is a Good Prognostic Marker for <scp>IPHC</scp> ‐ and Furmonertinib‐Based Treatment: A Case Report
The EGFR p.V774M/p.The S768I mutation contributed to improving the efficiency of furmonertinib-based therapy for NSCLC.
Authors
- W. Li
- Zizheng Song (ORCID: https://orcid.org/0000-0001-5647-2849)
- Yanan Wang (ORCID: https://orcid.org/0000-0003-1900-8400)
- Ling Hu (ORCID: https://orcid.org/0000-0001-7318-5091)
- Guanying Ren
- Xiaolei Wang (ORCID: https://orcid.org/0000-0001-8270-7517)
Institutions
- Affiliated Hospital of Hebei University (CN)
Publication Details
- Journal
- Cancer Reports
- Published
- 2025-12-30
- DOI
- https://doi.org/10.1002/cnr2.70444
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Hebei University